Pilot Study Evaluating Fecal Microbiota Transplant Treatment for Pediatric Small Intestinal Bacterial Overgrowth in Children Aged 3 to 18 Years

What this Trial Is About

Researchers are evaluating a new protocol of Fecal Microbiota Transplantation FMT to treat pediatric small intestinal bacterial overgrowth SIBO, focusing on children aged 3 to 18 years with intestinal resection. The study aims to assess the feasibility, safety, and short- and long-term clinical effectiveness of FMT in managing SIBO, a condition that can cause malabsorption, bloating, infections, and acidosis, especially in children with short bowel syndrome SBS. Participants will receive a single FMT infusion of about 50 grams of screened human stool prepared according to institutional standards. The infusion is administered via the childs existing enteral feeding tube or by elective upper endoscopy into the duodenum. Patients will stop antibiotics at least one week prior to FMT and will be monitored at one, four, and eight weeks after treatment. This open-label trial does not include randomization or placebo controls. Throughout the study, participants will undergo clinical symptom scoring, lactose breath testing, and biological sample collection including blood, stool, and urine at baseline and post-FMT timepoints. Researchers will track symptom changes, remission rates, microbial composition, and metabolic markers to evaluate treatment impact. Safety, acceptability, and recruitment rates will also be measured, with follow-up care coordinated through local institutions. The total participation spans eight weeks post-treatment.

Pilot Feasibility Study of Fecal Microbiota Transplant for the Treatment of Small Intestinal Bacterial Overgrowth